Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of HRF2105 Patch in Relieving Pain of Osteoarthritis
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06047483
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06035393
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
A Trial of SP2086 With Hepatic Insufficiency
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06035406
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT06015048
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06010680
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT06006104
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT05996380
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 317
- Registration Number
- NCT05994378
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT05983146
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05954169
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
© Copyright 2024. All Rights Reserved by MedPath